A 12 week, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of the extracts of lotus leaf complex in accordance with medical nutrition therapy on blood lipid levels in subjects with borderline dyslipidemia.

Korea Inspharm0 个研究点目标入组 68 人开始时间: 待定最近更新: 2019年3月11日

研究概览

暂无简介。

•A borderline dyslipidemia diagnosed with one of abnormalities of serum lipid level followed total cholesterol (200-239 mg/dl) or LDL-cholesterol (130-159 mg/dl) or triglyceride (150-199 mg/dl).

•1) subjects who were pregnant and breastfeeding or participating in other clinical trials within 3 months,
•2) subjects with secondary dyslipidemia due to hypothyroidism, nephritic syndrome or other diseases,
•3) subjects with cardiovascular diseases (angina pectoris, myocardial infarction and coronary artery bypass graft),
•4) subjects who had medical history of pancreatic diseases (e.g. pancreatitis or deficiency in pancreatic),
•5) subjects whose AST/ALT level was more than 3 times higher than the upper limit of the normal,
•6) subjects who were receiving hormone treatment,
•7) subjects of uncontrolled high blood pressure (over 170/100mmHg, when screened),
•8) subjects who had diabetes, which is hard to control blood glucose level,
•9) subjects who had been addicted to drugs or alcohol before,
•10) subjects who were illiteracy and
•11) subjects who were considered as inappropriate.

发起方

Korea Inspharm